ACIP review of the hepatitis B birth dose vaccination remains a grave concern - Please read more here.

Site Search

You searched for "hepatitis D"

  • First World Hepatitis Summit Focuses on Global Plan for Elimination by 2030

    … of the World Hepatitis Alliance, in his opening remarks at the Summit. “We must shift our energies from promoting just one day of awareness -- that is, World Hepatitis Day -- to creating awareness every day so that we can all live in a world without viral hepatitis.” With WHO taking a strong leadership position and launching the first global action plan, and more than 200 NGOs and patient advocacy groups dedicated to eliminating viral hepatitis, there is hope that the global pressure will move policy-makers in highly affected countries to make the investment and finally take action to end viral hepatitis.  

    http://www.hepb.org/blog/first-world-hepatitis-summit-focuses-on-global-plan-for-elimination-by-2030/
  • Join Hep B United and Watch the Hep B Summit Online!

    … (HBF) will discuss Hep B United accomplishments and 2014-2015 strategic priority areas HBU Mini Grants & Peer Mentor Program 4-4:40 p.m. Sunday:  The 2013-2014 Hep B United mini grant recipients and peer mentor groups will share their experiences and lessons learned in their campaigns against hepatitis B. Building Local Capacity 4:45-6 p.m. Sunday: Daniel Raymond (Harm Reduction Coalition), Christine Rodriguez (NVHR) and Isha Weerasinghe (AAPCHO) will lead a session on building capacity to improve effectiveness  at a local level. How to Frame Your HBV Story 11:30-2 p.m. Monday: Martha Hayward (Institute for Healthcare Improvement) will lead an interactive session on how to frame our hepatitis B stories in a compelling manner. Motivating & Growing Coalitions 1:15-2 p.m. Monday: Thaddeus Pham (Hep Free Hawaii) will help us to get motivated and grow local HBV coalitions for maximum impact! Not able to join the sessions with Periscope? Follow the conversation on Twitter using the #HepBSummit hashtag. Follow the events, RT and engage with event attendees and help us raise hepatitis B awareness. World Hepatitis Day is July 28th, and this is a terrific opportunity to let the world know what we’re doing to help those living with hepatitis B. Other popular hashtags for World Hepatitis Day include #PreventHepatitis, #WorldHepatitisDay, #4000voices,#hepatitis, #KnowHepB, and #justB . Be sure to join the World Hepatitis Alliance #4000voices Thunderclap Still have questions? Email us at info@hepb.org and we'll help you get started! Visit the Hep B United and Hepatitis B Foundation websites for more information about hepatitis B and related programs.

    http://www.hepb.org/blog/join-hep-b-united-and-partners-at-the-hep-b-summit/
  • I’m in love, when and how do I tell my (prospective) partner that I have hepatitis B?

    This is not an easy situation, and it is a challenge that is shared by many people living with hepatitis B. Before you share your hepatitis B status, you should be prepared. Make sure you are well-informed, because once you share the information, there will be questions you’ll need to answer. Have easy-to-understand resources, like Hepatitis B Foundation website pages, fact sheets or blogs, flagged or printed and ready to share. Additionally, you need to be prepared mentally for all sorts of reactions (both yours and theirs). People may feel supportive, surprised, fearful, or even angry. It is a good idea to talk to others with hepatitis B before you have this conversation, to get suggestions and advice. Talking to someone who has experienced this can help – and there are many people at www.hepbcommunity.org who will have had to disclose their hepatitis B to partners and other loved ones. Regardless of how the situation unfolds, please know that hepatitis B does not define who you are or what you can do! And be prepared that your relationship may change. If you find that your prospective partner is not receptive, you may learn that you’re better off without this person, as there are many challenges occurring in a lifetime. It’s important to have a supportive partner! You can find in-depth response to this important question on these blog articles: Romance in the Air? Take a deep breath and disclose How do I Share My Hepatitis B Status Dating and Hepatitis B – A personal perspective     Find more Frequently Asked Questions here.    Page updated 12/27/2022

    https://www.hepb.org/what-is-hepatitis-b/faqs/im-in-love-when-and-how-do-i-tell-my-prospective-partner-that-i-have-hepatitis-b/
  • Webinar on Treatment Options for Liver Cancer: What You Need to Know

      Please join the Hepatitis B Foundation’s Liver Cancer Connect program and world-renowned liver disease specialist, Dr. Robert Gish for a webinar on Monday, April 27th 12 noon EDT to learn about liver cancer treatment. How does the stage of the cancer affect treatment? Why are screening and surveillance so important? What are the available treatments and what are the therapies in development? Liver Cancer is the 2nd leading cause of cancer related deaths and the 6th most common cancer worldwide. But it’s not all doom and gloom. Often liver cancer can be prevented through vaccination against hepatitis B and control of the other main risk factors for liver cancer, which include chronic viral hepatitis B and C, cirrhosis, excessive alcohol use, nonalcoholic fatty liver disease, obesity, and aflatoxins. And if detected early, liver cancer can be treated or cured with liver surgery or transplantation. Screening and surveillance are essential for early dection of liver cancer, which allows for more treatment options, with a greater chance of successful results. Dr. Gish will outline currently available treatment options and will review the promising new therapies in development. Please join us and learn more. Register here for the free webinar. Dr. Robert G. Gish, a Professor Consultant, Stanford University, and Medical Director of the Hepatitis B Foundation, is an internationally renowned medical researcher in viral hepatitis. Dr. Gish has made invaluable contributions to the understanding and treatment of viral hepatitis and liver cancer. This webinar is presented by the Hepatitis B Foundation and its dedicated liver cancer program, Liver Cancer Connect, in collaboration with Blue Faery: The Adrienne Wilson Liver Cancer Association.

    http://www.hepb.org/blog/webinar-on-treatment-options-for-liver-cancer-what-you-need-to-know/
  • Fighting the Doom and Gloom: Prevention Works!

    … damage to liver cancer, and preventing recurrence of liver cancer after liver resection. Perhaps the most exciting recent news in the hepatitis world is that hepatitis C— the leading cause of liver cancer in the United States— is now curable! This is a remarkable advance in the fight against liver cancer. And nonalcoholic fatty liver disease, which is increasingly emerging as a risk factor for liver cancer, can be prevented with healthy diets and lifestyles. Of course, vaccines and antiviral drugs are only effective when used. Unfortunately, the vast majority of people with chronic hepatitis don’t know they are infected and therefore do not seek or receive treatment. To address this, the US Preventive Services Task Force recently recommended hepatitis B screening in high-risk ethnic groups. And the Centers for Disease Control and Prevention is recommending that all baby boomers (those born between 1945 through 1965) get tested for hepatitis C. People who have not been infected with hepatitis B can get the hepatitis B vaccine, which offers lifelong protection against hepatitis B. And people with hepatitis C now have a cure. People at high risk for liver cancer should undergo screening and regular testing (surveillance) for early detection of the cancer. In our next blog, find out who should be screened and how screening and surveillance save lives!

    http://www.hepb.org/blog/fighting-the-doom-and-gloom-prevention-works/
  • Hepatitis is Still the Silent Killer

    Great way to wrap up World Hepatitis Day events with a commentary from our viral hepatitis champions on Capitol Hill. A big thank you to Senator Mazie K. Hirono and Representatives, Michael M. Honda, Hank Johnson, and Bill Cassidy for their tireless efforts. Viral Hepatitis is a problem we cannot ignore! Roll Call (online) By Sen. Mazie K. Hirono, and Reps. Michael M. Honda, Hank Johnson, and Bill Cassidy. July 31, 2014, 5 a.m. Although the price of a revolutionary new hepatitis C treatment has made headlines recently, the real hepatitis crisis continues largely unreported. A more immediate problem for many Americans is not how much one hepatitis C treatment might cost; it is how many Americans are infected with viral hepatitis and do not even know it. World Hepatitis Day, July 28, reminds us that more than 5 million Americans — or 2 percent of the population — are living with viral hepatitis. Yet the Centers for Disease Control and Prevention (CDC) estimates as many as 75 percent of these Americans are unaware they have the virus. This “silent killer” goes undetected because the virus often remains asymptomatic until it has already wreaked havoc on the liver, causing cirrhosis, end-stage liver disease, or liver cancer. According to the CDC, more than 30 percent of infected individuals will develop one of these conditions. Meanwhile, since the majority of infected individuals don’t realize they have hepatitis, they do not take the necessary precautions and can unknowingly transmit the virus to others. More Americans die every year from hepatitis C than HIV. Without effective intervention, it is estimated that deaths due to the hepatitis C virus will double, or even triple, in the next 20 years. Baby boomers — Americans born between 1945 and 1965 — make up 75 percent of Americans with hepatitis C, and are five times more likely to have the virus than the general population. Hepatitis disproportionately affects communities of color. One in 12

    http://www.hepb.org/blog/hepatitis-is-still-the-silent-killer/
  • HBF applauds President Biden’s Memorandum denouncing racism, xenophobia, and intolerance against Asian Americans and Pacific Islanders

    January 27, 2021 - The Hepatitis B Foundation applauds President Biden’s Memorandum denouncing racism, xenophobia, and intolerance against Asian Americans and Pacific Islanders, which increased during the COVID-19 pandemic. The racist and inflammatory terms used to attack and blame Asian American communities for the cause of the pandemic exacerbates racial health inequities and discrimination against populations that continue to face barriers to health care access and are at increased risk of highly stigmatized conditions like chronic hepatitis B infection. The memorandum encourages agencies to consult with public health experts, AAPI community leaders, or AAPI community-serving organizations to ensure an understanding of the needs and challenges faced by AAPI communities. The Hepatitis B Foundation applauds this timely commitment to mitigate inequalities among AAPIs especially since the COVID-19 pandemic has disproportionately affected Native Hawaiians and Pacific Islander communities. The Hepatitis B Foundation looks forward to working with the Biden Administration, community and federal partners, and other key stakeholders to address the significant disparities and inequalities affecting the Asian American and Pacific Islander communities like disproportionate hepatitis B-related mortality rates.

    https://www.hepb.org/news-and-events/news-2/hbf-applauds-president-bidens-memorandum-denouncing-racism-xenophobia-and-intolerance-against-asian-americans-and-pacific-islanders/
  • Joan Block Improving Lives Fund

    Honoring Joan Block – Co-Founder and Former Executive Director of HBFContinuing a Legacy of Improving the Lives of People Affected by Hepatitis B For 26 years, Joan Block has been leading the charge and keeping the beacon of hope shining for millions of people around the world who are touched by hepatitis B. In June 2017, Joan stepped down as the Executive Director of the Hepatitis B Foundation, and passing the torch to a new leader who will help guide the HBF into a new chapter of growth and development. But the purpose to which she has dedicated her life is not going away. Joan can’t be replaced, but we can honor her passionate commitment to the cause and simultaneously create the means to help the HBF continue to do what she did – directing resources where the opportunity is greatest or the need is most critical to improve the lives of those affected by hepatitis B. Donors who want to celebrate and perpetuate Joan’s legacy have set a bold goal of raising $150,000 to establish the Joan Block Improving Lives Fund of the Hepatitis B Foundation. The Fund will be a resource for: Leading advocacy efforts to increase attention and funding for hepatitis B; Ending discrimination against people with hepatitis B; Changing policies and practices to increase screening, prevention and linkage to care for hepatitis B; and Improving the lives of people affected by hepatitis B. Please consider honoring Joan's leadership and advocacy with a gift to the Joan Block Improving Lives Fund. Click here to read the detailed Case Statement about the Joan Block Improving Lives Fund.

    https://www.hepb.org/donate/joan-block-improving-lives-fund/
  • Targets to Eliminate Hepatitis B in U.S.

    U.S. National Academies of Sciences Report Concludes Hepatitis B Mortality Can Be Cut 50% Doylestown, PA (March 28, 2017) – The Hepatitis B Foundation commends the U.S. National Academies of Sciences, Engineering, and Medicine (NASEM) report, A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report, that concludes a 50 percent reduction in mortality from chronic hepatitis B infection, as well as elimination of mother-to-child transmission of hepatitis B, is possible in the United States by 2030 with appropriate prioritization and resources. As a result of reducing hepatitis B, there would be a decrease of hepatocellular carcinoma (HCC or primary liver cancer) by about one-third since hepatitis B is a leading cause of HCC, a decrease of hepatitis B-related cirrhosis by about 45 percent, and the prevention of more than 60,000 deaths nationwide over the next decade. Hepatitis B is a deadly liver infection caused by the hepatitis B virus (HBV). In the U.S., it is estimated that over 2 million Americans are living with chronic HBV infection, only 25 percent are aware of their infection, and less than 10 percent of infected individuals are able to access care and treatment. The NASEM committee set targets for HBV elimination, reporting that meeting the stated goals would require diagnosing 90 percent of cases, linking 90 percent of cases to care, and treating 80 percent of cases. The NASEM report is the U.S. response to the World Health Organization’s call for countries to eliminate viral hepatitis as a major public health problem by 2030, and it recommends specific actions towards the elimination of hepatitis B and C within five key areas: information, interventions, service delivery, financing and research. “The report confirms significant improvements are needed to increase life-saving screening and access to care and treatment of hepatitis B,” said Joan Block RN, BSN, co-founder and executive director of the Hepatitis B Foundation. “The U.S. targets are bold and possible, but it will require the political will and investment in resources to achieve these ambitious goals.” “We agree that a critical investment in hepatitis B research is needed, with priority given to finding a cure,” responded Chari Cohen, DrPH, MPH, director of public health at the Hepatitis B Foundation. “Together with an already effective vaccine, a cure for hepatitis B would truly make hepatitis B history.” Investing in hepatitis B cure research is a key research area highlighted in the report, along with creating a standard national public health surveillance system; improving capacity for providers to screen, manage and treat patients; and identifying effective strategies for improving risk-based screening and linkage to care rates in hard to reach populations. Read the complete report, A National Strategy for the Elimination of Hepatitis B and C: Phase Two Report, prepared by the National Academies of Sciences, Engineering, and Medicine on its website at www.nationalacademies.org/HepatitisElimination. About the Hepatitis B Foundation - The Hepatitis B Foundation is the nation’s leading nonprofit organization solely dedicated to finding a cure for hepatitis B and improving the quality of life for those affected worldwide through research, education and patient advocacy. To learn more, go to www.hepb.org, read our blog at hepb.org/blog, follow us on Twitter @HepBFoundation, find us on Facebook at facebook.com/hepbfoundation or call 215-489-4900. ###  

    https://www.hepb.org/news-and-events/news-2/hepatitis-b-foundation-commends-targets-to-eliminate-hepatitis-b-in-u-s-by-2030/
  • Princeton Workshop

    Princeton Workshop 2002 included the following attendees: Harvey Alter, Timothy Block, Baruch Blumberg, Deb Birnkrant, Carol Brosgart, Nat Brown, Antonio Bertoletti, Alessia Ciancio, Paul Cote, Mark Feitelson, John Gerin, Jay Hoofnagle, Leslye Johnson, Brent Korba, Thomas London, William Mason, Brian McMahon, Anand Mehta, Charles Rogler, C. Satishchandran, Raymond Schinazi, Robert Schneider, Marvin Siegel, David Standring, Lorne Tyrrell, Robert Whalen, and Shelly Xiong. In 1995, the Hepatitis B Foundation initiated a novel concept – to host a meeting that would bring together in one room a small group of the world’s thought leaders from academe, industry and government for highly focused roundtable discussions of new and innovative therapeutic strategies for chronic hepatitis B. Today, the prestigious Princeton Workshop serves an important role in promoting international scientific exchange and collaborations dedicated to the problem of hepatitis B. Despite the crowded scientific conference schedule, the Princeton Workshop continues to draw leaders in the field because of its small size and unique format. “Some of the most influential leaders in the field are invited to our workshop, which has minimal structure, allowing for a vigorous exchange of ideas,” said Dr. Timothy Block, HBF co-founder and president. “It’s unique from all other scientific meetings because it encourages interactive discussion at a level that is unprecedented, and fosters new relationships and research collaborations that would not occur otherwise.” And new research directions, Block added. For example, the list of HBV Research Priorities identified at the 2000 Princeton Workshop were part of the National Institutes of Health first 10-Year Liver Disease Action Plan, published in 2004. And the 2017 workshop focused the findings of the comprehensive Roadmap for a Cure: Priority Areas for Chronic Hepatitis B and Liver Cancer Research. “What makes the meeting special is that it always combines basic scientists and academics with those in the pharmaceutical industry who actually make the drugs,” said W. Thomas London, M.D., senior scientist at the Fox Chase Cancer Center in Philadelphia, PA. Because there are no formal workshop proceedings published, pharmaceutical executives can freely discuss – up to a point – what they are working on. Today, the Princeton Workshop is held annually, and alternates between two day sessions in Princeton, NJ and a special symposium in Hawaii, in conjunction with the larger HepDART meeting. The Princeton Workshop is free and by invitation only. Princeton Workshop Summaries 2022 Workshop 2017 Workshop 2015 Workshop 2013 Workshop 2011 Workshop 2008 Workshop 2006 Workshop 2004 Workshop 2003 Workshop 2002 Workshop 2001 Workshop 2000 Workshop

    https://www.hepb.org/news-and-events/princeton-workshop/